Transparency Market Research
Companion Diagnostics Market Size to Hit USD 9.3 Billion Revenue by 2028 with 9% CAGR: Report by Transparency Market Research
20 août 2024 10h38 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 20, 2024 (GLOBE NEWSWIRE) -- The global companion diagnostics market (동반진단 시장) was worth US$ 5.2 Bn in 2020 and is...
Turnstone Logo.jpg
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
14 août 2024 16h01 HE | Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
12 août 2024 08h00 HE | Compass Therapeutics
Compass Therapeutics announces 2nd quarter results and provides clinical results update
Cardiff.jpg
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
01 août 2024 16h05 HE | Cardiff Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
logo 600X600.png
U.S. Colorectal Cancer Screening Market is Expected to Reach US$ 10,618.9 Million by 2031, CoherentMI
11 juil. 2024 04h00 HE | CMI
Burlingame, July 11, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, U.S. Colorectal Cancer Screening Market is estimated to value at US$ 5,952.2 Million in the year 2024, and is...
Qu Biologics.png
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
06 juin 2024 08h00 HE | Qu Biologics, Inc.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
treos logo.jpg
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
03 juin 2024 07h00 HE | Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Global Precision Oncology Market
$163 Billion Precision Oncology Markets - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2023 & 2024-2029F
14 mai 2024 02h52 HE | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Precision Oncology Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
13 mai 2024 08h00 HE | Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
treos logo.jpg
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
08 mai 2024 07h45 HE | Treos Bio Corp.
LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...